At March 31, 2026 and December 31, 2025, accrued expenses consisted of the following (in thousands):
As of March 31, 2026
As of December 31, 2025
Accrued compensation
$
7,413
9,467
Accrued clinical trial costs
12,846
8,336
Accrued other research and development costs
824
1,238
Professional services
2,827
895
Other accruals
604
510
Total
24,514
20,446
No definition available.
Tabular disclosure of the components of accrued liabilities.